Workflow
OssDsign Catalyst
icon
Search documents
Interim Report - January-June 2025
Globenewswire· 2025-08-29 06:00
Core Viewpoint - Karolinska Development AB emphasizes its clear strategy and stable scientific foundation for its investment portfolio, focusing on patient benefits amidst challenging market conditions [1]. Significant Events - Organon plans to discontinue the clinical development of drug candidate OG-6219, following Phase 2 study results [3]. - Umecrine Cognition presented preclinical data on golexanolone's effects on Parkinsonian symptoms at the AD/PD 2025 conference [4]. - Umecrine Cognition received a USD 420,000 research grant from The Michael J. Fox Foundation for golexanolone studies [4]. - OssDsign achieved a milestone of treating 10,000 patients with its bone graft product in the US market [4]. - Karolinska Development divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million [4]. Financial Update - The net profit/loss for Q2 2025 was SEK -73.3 million, compared to SEK -16.0 million in Q2 2024 [5]. - The total fair value of the portfolio decreased to SEK 1,384.9 million at the end of June 2025, down from SEK 1,434.2 million [5]. - Net asset value at the end of June 2025 was SEK 1,148.6 million, or SEK 4.3 per share, compared to SEK 1,238.2 million, or SEK 4.6 per share, at the end of June 2024 [5]. - Cash and cash equivalents increased by SEK 20.0 million, totaling SEK 71.1 million on June 30, 2025 [5].
Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US
Globenewswire· 2025-05-13 10:45
Core Insights - OssDsign has successfully treated 10,000 patients with its innovative nanosynthetic bone graft, OssDsign Catalyst, in the US market [1][2] - The product has shown rapid and robust bone formation, even in poorly vascularized environments, and has significantly penetrated the American orthobiologics market since its launch in August 2021 [2][3] - The usage of OssDsign Catalyst has doubled from 5,000 patients reported last year, indicating strong demand from American surgeons and hospitals [3] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [4][5] - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [6]
Karolinska Development portfolio company OssDsign will change CEO during second half of 2025
Globenewswire· 2025-04-30 10:40
Group 1 - Karolinska Development's portfolio company OssDsign is undergoing a leadership change to enhance its focus on the US market [1][2] - OssDsign has transitioned to a pure-play orthobiologics company since launching OssDsign Catalyst in the US in August 2021, experiencing high double-digit growth [2] - Current CEO Morten Henneveld will ensure a smooth transition to new leadership and will leave his position by year-end or upon the appointment of a new CEO [3] Group 2 - Karolinska Development holds a 3% ownership stake in OssDsign [3] - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that develop these innovations into commercial products [4][5] - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [6]